A detailed history of Parkman Healthcare Partners LLC transactions in Alpha Teknova, Inc. stock. As of the latest transaction made, Parkman Healthcare Partners LLC holds 296,652 shares of TKNO stock, worth $1.89 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
296,652
Previous 296,202 0.15%
Holding current value
$1.89 Million
Previous $784,000 48.21%
% of portfolio
0.06%
Previous 0.11%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$1.29 - $2.81 $580 - $1,264
450 Added 0.15%
296,652 $406,000
Q1 2024

May 15, 2024

BUY
$2.41 - $3.88 $33,658 - $54,188
13,966 Added 4.95%
296,202 $784,000
Q4 2023

Feb 14, 2024

BUY
$1.85 - $3.73 $89,706 - $180,867
48,490 Added 20.74%
282,236 $1.05 Million
Q3 2023

Nov 14, 2023

BUY
$1.66 - $3.83 $95,337 - $219,964
57,432 Added 32.57%
233,746 $652,000
Q2 2023

Aug 11, 2023

BUY
$1.8 - $3.98 $45,106 - $99,734
25,059 Added 16.57%
176,314 $470,000
Q1 2023

May 12, 2023

BUY
$2.74 - $6.25 $62,463 - $142,481
22,797 Added 17.75%
151,255 $447,000
Q4 2022

Feb 13, 2023

BUY
$3.23 - $5.64 $22,719 - $39,671
7,034 Added 5.79%
128,458 $724,000
Q3 2022

Nov 14, 2022

BUY
$3.34 - $9.2 $4,766 - $13,128
1,427 Added 1.19%
121,424 $406,000
Q2 2022

Aug 12, 2022

BUY
$6.39 - $16.24 $3,380 - $8,590
529 Added 0.44%
119,997 $1.01 Million
Q1 2022

May 13, 2022

BUY
$12.79 - $21.64 $182,385 - $308,586
14,260 Added 13.55%
119,468 $1.65 Million
Q4 2021

Feb 11, 2022

BUY
$17.49 - $26.72 $416,891 - $636,897
23,836 Added 29.29%
105,208 $2.16 Million
Q3 2021

Nov 12, 2021

BUY
$17.47 - $27.49 $1.42 Million - $2.24 Million
81,372 New
81,372 $2.03 Million

Others Institutions Holding TKNO

About Alpha Teknova, Inc.


  • Ticker TKNO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 28,080,500
  • Market Cap $179M
  • Description
  • Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; ...
More about TKNO
Track This Portfolio

Track Parkman Healthcare Partners LLC Portfolio

Follow Parkman Healthcare Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parkman Healthcare Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parkman Healthcare Partners LLC with notifications on news.